MedPath

Nanjing NingQi Medicine Science and Technology Co., Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial

Phase 3
Conditions
Chemotherapy-induced Peripheral Neuropathy
Colorectal Cancer
Interventions
Drug: Mimetic granules of Yiqi-Wenjing prescriptions
Drug: Huangqi-Guizhi-Wuwu granules
Drug: Danggui-Sini granules
First Posted Date
2020-12-30
Last Posted Date
2020-12-30
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
360
Registration Number
NCT04690283

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Phase 2
Conditions
Peripheral T-cell Lymphomas
Interventions
Drug: GDP
Biological: Endostar
First Posted Date
2015-08-11
Last Posted Date
2015-08-11
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02520219
Locations
🇨🇳

Jiangsu province tumor hospital, Nanjing City, Jiangsu, China

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Phase 4
Conditions
Non-small Cell Lung Cancer
Interventions
Biological: Endostar
Drug: Changchun marina
Drug: cisplatin
Drug: Taxol
Drug: parapl
First Posted Date
2015-07-31
Last Posted Date
2015-08-04
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
400
Registration Number
NCT02513355
Locations
🇨🇳

Jiangsu Taizhou People's Hospital, Nanjing City, Jiangsu, China

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Phase 4
Conditions
Advanced Lung Squamous Carcinoma
Interventions
Biological: Endostar
Drug: Docetaxel
Drug: Cisplatin
First Posted Date
2015-07-31
Last Posted Date
2015-07-31
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
400
Registration Number
NCT02513342
Locations
🇨🇳

Jinling Hospital, Nanjing, Jiangsu, China

🇨🇳

The first affiliated hospital of soochow university, Soochow, Jiangsu, China

Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

Phase 2
Conditions
Colon Cancer
Interventions
Drug: mFOLFOX6
Drug: XELOX
Drug: Placebo ChangTai Keli
Drug: ChangTai Keli
First Posted Date
2015-07-28
Last Posted Date
2015-08-03
Lead Sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Target Recruit Count
360
Registration Number
NCT02510118
Locations
🇨🇳

Jiege Huo, Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy